tiprankstipranks
Fusion Antibodies Expands Collaboration with NCI
Company Announcements

Fusion Antibodies Expands Collaboration with NCI

Fusion Antibodies Plc (GB:FAB) has released an update.

Invest with Confidence:

Fusion Antibodies Plc has announced an expansion of their collaboration with the National Cancer Institute to include the humanisation of camelid nanobodies, which shows promise for CAR-T therapy applications. The company, known for its work in pre-clinical antibody discovery and engineering, aims to support the NCI in advancing these therapies toward clinical success. Fusion Antibodies, established in 2001 and listed on AIM since 2017, offers a suite of services to aid in the development of therapeutic drugs and diagnostic applications.

For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles